Overview

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Status:
Not yet recruiting
Trial end date:
2028-01-25
Target enrollment:
Participant gender:
Summary
The main aims of this study is to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.
Phase:
Phase 1
Details
Lead Sponsor:
Takeda
Treatments:
Bortezomib
Daratumumab
Lenalidomide
Pomalidomide